314 related articles for article (PubMed ID: 36383021)
1. Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.
Soto JA; Melo-González F; Gutierrez-Vera C; Schultz BM; Berríos-Rojas RV; Rivera-Pérez D; Piña-Iturbe A; Hoppe-Elsholz G; Duarte LF; Vázquez Y; Moreno-Tapia D; Ríos M; Palacios PA; Garcia-Betancourt R; Santibañez Á; Pacheco GA; Mendez C; Andrade CA; Silva PH; Diethelm-Varela B; Astudillo P; Calvo M; Cárdenas A; González M; Goldsack M; Gutiérrez V; Potin M; Schilling A; Tapia LI; Twele L; Villena R; Grifoni A; Sette A; Weiskopf D; Fasce RA; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Retamal-Díaz A; Muñoz-Jofré N; ; Meng X; Xin Q; Alarcón-Bustamante E; González-Aramundiz JV; Le Corre N; Álvarez-Figueroa MJ; González PA; Abarca K; Perret C; Carreño LJ; Bueno SM; Kalergis AM
mBio; 2022 Dec; 13(6):e0131122. PubMed ID: 36383021
[TBL] [Abstract][Full Text] [Related]
2. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
[TBL] [Abstract][Full Text] [Related]
3. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
Han B; Song Y; Li C; Yang W; Ma Q; Jiang Z; Li M; Lian X; Jiao W; Wang L; Shu Q; Wu Z; Zhao Y; Li Q; Gao Q
Lancet Infect Dis; 2021 Dec; 21(12):1645-1653. PubMed ID: 34197764
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
[TBL] [Abstract][Full Text] [Related]
7. Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.
Bueno SM; Abarca K; González PA; Gálvez NMS; Soto JA; Duarte LF; Schultz BM; Pacheco GA; González LA; Vázquez Y; Ríos M; Melo-González F; Rivera-Pérez D; Iturriaga C; Urzúa M; Domínguez A; Andrade CA; Berríos-Rojas RV; Canedo-Marroquín G; Covián C; Moreno-Tapia D; Saavedra F; Vallejos OP; Donato P; Espinoza P; Fuentes D; González M; Guzmán P; Muñoz Venturelli P; Pérez CM; Potin M; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Oyarzún-Arrau A; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Sette A; Zeng G; Meng W; González-Aramundiz JV; Kalergis AM
Clin Infect Dis; 2022 Aug; 75(1):e792-e804. PubMed ID: 34537835
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
[TBL] [Abstract][Full Text] [Related]
9. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
10. Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.
Rivera-Pérez D; Méndez C; Diethelm-Varela B; Melo-González F; Vázquez Y; Meng X; Xin Q; Fasce RA; Fernández J; Mora J; Ramirez E; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Grifoni A; Weiskopf D; Sette A; Astudillo P; Le Corre N; Abarca K; Perret C; González PA; Soto JA; Bueno SM; Kalergis AM
Front Immunol; 2024; 15():1372193. PubMed ID: 38812507
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients.
Chen Y; Zhao T; Chen L; Jiang G; Geng Y; Li W; Yin S; Tong X; Tao Y; Ni J; Lu Q; Ning M; Wu C
mBio; 2024 Apr; 15(4):e0240723. PubMed ID: 38456703
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Zeng G; Wu Q; Pan H; Li M; Yang J; Wang L; Wu Z; Jiang D; Deng X; Chu K; Zheng W; Wang L; Lu W; Han B; Zhao Y; Zhu F; Yu H; Yin W
Lancet Infect Dis; 2022 Apr; 22(4):483-495. PubMed ID: 34890537
[TBL] [Abstract][Full Text] [Related]
13. Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile.
Díaz-Dinamarca DA; Díaz P; Barra G; Puentes R; Arata L; Grossolli J; Riveros-Rodriguez B; Ardiles L; Santelises J; Vasquez-Saez V; Escobar DF; Soto D; Canales C; Díaz J; Lamperti L; Castillo D; Urra M; Zuñiga F; Ormazabal V; Nova-Lamperti E; Benítez R; Rivera A; Cortes CP; Valenzuela MT; García-Escorza HE; Vasquez AE
Front Public Health; 2023; 11():1229045. PubMed ID: 37693706
[TBL] [Abstract][Full Text] [Related]
14. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial.
Bueno SM; Abarca K; González PA; Gálvez NM; Soto JA; Duarte LF; Schultz BM; Pacheco GA; González LA; Vázquez Y; Ríos M; Melo-González F; Rivera-Pérez D; Iturriaga C; Urzúa M; Dominguez A; Andrade CA; Berrios RV; Canedo-Marroquín G; Covián C; Moreno-Tapia D; Saavedra F; Vallejos OP; Donato P; Espinoza P; Fuentes D; González M; Guzmán P; Muñoz-Venturelli P; Pérez CM; Potin M; Rojas A; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Oyarzún-Arrau A; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Sette A; Zeng G; Meng W; González-Aramundiz JV; Kalergis AM
medRxiv; 2021 Apr; ():. PubMed ID: 35441164
[TBL] [Abstract][Full Text] [Related]
15. Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.
Gálvez NMS; Pacheco GA; Schultz BM; Melo-González F; Soto JA; Duarte LF; González LA; Rivera-Pérez D; Ríos M; Berrios RV; Vázquez Y; Moreno-Tapia D; Vallejos OP; Andrade CA; Hoppe-Elsholz G; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; Johnson M; Goldblatt D; González PA; Abarca K; Bueno SM; Kalergis AM
Elife; 2022 Oct; 11():. PubMed ID: 36226829
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
Omma A; Batirel A; Aydin M; Yilmaz Karadag F; Erden A; Kucuksahin O; Armagan B; Güven SC; Karakas O; Gokdemir S; Altunal LN; Buber AA; Gemcioglu E; Zengin O; Inan O; Sahiner ES; Korukluoglu G; Sezer Z; Ozdarendeli A; Kara A; Ates I
Hum Vaccin Immunother; 2022 Nov; 18(6):2122503. PubMed ID: 36315843
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial.
Hu J; Liu Y; Liu S; Shu Q; Yang X; Chu K; Qiao Y; Hu Y; Wang K; Pan H
Front Immunol; 2023; 14():1241153. PubMed ID: 37799724
[TBL] [Abstract][Full Text] [Related]
18. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
19. Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.
Zhao W; Chen W; Li J; Chen M; Li Q; Lv M; Zhou S; Bai S; Wang Y; Zhang L; Zhang P; Wang J; Zheng Q; Wu J
mBio; 2022 Jun; 13(3):e0018122. PubMed ID: 35475648
[TBL] [Abstract][Full Text] [Related]
20. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.
Muena NA; García-Salum T; Pardo-Roa C; Avendaño MJ; Serrano EF; Levican J; Almonacid LI; Valenzuela G; Poblete E; Strohmeier S; Salinas E; Muñoz A; Haslwanter D; Dieterle ME; Jangra RK; Chandran K; González C; Riquelme A; Krammer F; Tischler ND; Medina RA
EBioMedicine; 2022 Apr; 78():103972. PubMed ID: 35366624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
